Obesity and associated chronic inflammation were shown to facilitate breast cancer (BC)
growth and metastasis. Leptin, adiponectin, estrogen, and several pro-inflammatory …

Triple-negative breast cancer (TNBC) is diagnosed more frequently in younger and
premenopausal women and is highly prevalent in African American women. TNBC is a term …

DNA repair competency is one determinant of sensitivity to certain chemotherapy drugs,
such as cisplatin. Cancer cells with intact DNA repair can avoid the accumulation of genome …

Purpose Cisplatin is a chemotherapeutic agent not used routinely for breast cancer
treatment. As a DNA cross-linking agent, cisplatin may be effective treatment for hereditary …

Background Platinum chemotherapy has a role in the treatment of metastatic triple-negative
breast cancer but its full potential has probably not yet been reached. We assessed whether …

Germline mutations in the BRCA1, BRCA2 and Fanconi anaemia genes confer cancer
susceptibility, and the proteins encoded by these genes have distinct functions in related …

One of the obstacles limiting progress in the development of effective cancer therapies is the
shortage of preclinical models that capture the dynamic nature of tumor microenvironments …

The aim of this study is to estimate the frequency of pathologic complete response (pCR)
after neoadjuvant treatment with cisplatin chemotherapy in women with breast cancer and a …

Background The ability of urinary biomarkers to complement established clinical risk
prediction models for postoperative adverse kidney events is unclear. We assessed the …

The discovery of the first gene associated with hereditary breast cancer, BRCA1, was
anticipated to greatly increase our understanding of both hereditary and sporadic forms of …